Saturday 17 October 2026 Export RXRX’s income statement to Excel — free account

Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024. In the quarter to June 2026, revenue fell 60.1%, EPS grew 39.0%, free cash flow fell 32.0% and total debt fell 66.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

3.47 0.69 −16.59%

Follow RXRX

Alert me

Market cap: $2.2B
P/E: 0.0×
Fwd P/E: −3.8×
Dividend yield: —
F-score: 3/9
Altman Z: 0.37
Beneish M: −1.72
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
P/E ratio Full definition →	+8 more quarters Free account	0.00	0.00	0.00	0.00
P/S ratio Full definition →		49.93	24.51	24.47	35.62
P/FCF ratio Full definition →		0.00	0.00	0.00	0.00
P/Operating CF Full definition →		(18.59)	(39.72)	(20.04)	(18.44)
P/B ratio Full definition →		2.08	1.62	1.59	2.14
Price to Tangible BV Full definition →		3.88	2.78	2.85	4.14
EV/Sales Full definition →		35.03	14.62	14.64	25.66
EV/EBITDA Full definition →		0.00	0.00	0.00	0.00
EV/Operating CF Full definition →		(3.47)	(2.94)	(3.03)	(4.02)
EV/FCF Full definition →		(3.40)	(2.87)	(2.96)	(3.97)
Quick Ratio Full definition →		4.42	5.23	5.19	4.72
Current Ratio Full definition →		4.60	5.50	5.47	5.03
Net Debt/EBITDA Full definition →		4.31	8.31	6.00	4.68
Debt/Assets Full definition →		0.85%	0.65%	0.54%	0.39%
Debt/Equity Full definition →		0.01	0.01	0.01	0.01
Asset Turnover Full definition →		0.04	0.05	0.05	0.04
Operating CF/Net income Full definition →		0.72	0.43	0.69	0.81
Capex/Depreciation Full definition →		(0.01)	(0.06)	(0.02)	(0.11)
Research and Development Expense of Revenue Full definition →		2,339.36%	269.96%	1,358.10%	1,168.37%
Selling, General and Administrative Expense of Revenue Full definition →		804.41%	94.71%	534.47%	541.50%
Intangible Assets out of Total Assets Full definition →		0.35	0.32	0.34	0.37
Share Based Compensation of Revenue Full definition →		487.79%	66.87%	343.25%	254.21%
Graham Net Nets Full definition →		0.17	0.26	0.24	0.16
Graham Number Full definition →		0.00	0.00	0.00	0.00
Earnings Yield Full definition →		(36.89%)	(36.19%)	(39.09%)	(28.34%)
Free Cash Flow Yield Full definition →		(20.64%)	(20.79%)	(20.19%)	(18.13%)
Revenue per Share Full definition →		0.01	0.08	0.01	0.01
Operating CF per Share Full definition →		(0.26)	(0.10)	(0.15)	(0.20)
Capex per Share Full definition →		0.00	0.00	0.00	0.00
Free Cash Flow per Share Full definition →		(0.26)	(0.11)	(0.15)	(0.20)
Cash per Share Full definition →		1.48	1.67	1.25	1.03
Shareholders Equity per Share Full definition →		2.34	2.53	1.94	1.72
Interest Debt per Share Full definition →		0.00	0.00	0.00	0.00
Book value per Share Full definition →		2.34	2.53	1.94	1.72
Free Cash Flow Full definition →		(117.60)	(47.32)	(81.44)	(107.91)
Working Capital Full definition →		559.00	665.14	579.86	483.58
Capital Expenditures Full definition →		(0.24)	(1.24)	(0.34)	(1.96)
Net Current Asset Value Full definition →		361.53	469.58	394.80	305.80
EV/EBIT Full definition →		0.00	0.00	0.00	0.00
Capex to Sales Full definition →		0.05	0.04	0.05	0.26
Price to Operating Income Full definition →		0.00	0.00	0.00	0.00
Other line items
Average Receivables Full definition →		12.08	36.91	29.85	18.00
Average Payables Full definition →		8.10	19.87	22.72	15.99
Average Assets Full definition →		1,063.01	1,461.36	1,322.38	1,257.51
Average Common Equity Full definition →		785.75	1,082.82	979.36	917.07

Show all line items

Columns are period end dates

Stockrow Weekly